Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 6, 2014, Pages 3979-3985

  Sonoda, Shozo ^a   Sakamoto, Taiji ^a   Yamashita, Takehiro ^a   Otsuka, Hiroki ^a   Shirasawa, Makoto ^a   Kakiuchi, Naoko ^a   Uchino, Eisuke ^a   Terasaki, Hiroto ^a   Kawano, Hiroki ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Choroid; Diabetic retinopathy; Steroid

Indexed keywords

ANTIGLAUCOMA AGENT; ANTIINFECTIVE AGENT; BEVACIZUMAB; MAQAID; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFECT; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTERVENTION STUDY; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIGNAL NOISE RATIO; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBFOVEAL CHOROIDAL THICKNESS; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

CHOROID; DIABETIC RETINOPATHY; STEROID;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INTERVENTION STUDIES; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 84903377423     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-14188     Document Type: Article

References (34)

1. Sloan FA, Belsky D, Ruiz D Jr, Lee P. Changes in incidence of diabetes mellitus-related eye disease among US elderly persons, 1994-2005. Arch Ophthalmol. 2008; 126: 1548-1553.
2. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012; 366: 1227-1239.
3. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report No. 1. Arch Ophthalmol. 1985; 103: 1796-1806.
4. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117: 1064-1077.
5. Smiddy WE. Clinical applications of cost analysis of diabetic macular edema treatments. Ophthalmology. 2012; 119: 2558-2562.
6. McLeod DS, Lefer DJ, Merges C, Lutty GA. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol. 1995; 147: 642-653.
7. Fryczkowski AW, Sato SE, Hodes BL. Changes in the diabetic choroidal vasculature: scanning electron microscopy findings. Ann Ophthalmol. 1988; 20: 299-305.
8. Hidayat AA, Fine BS. Diabetic choroidopathy. Light and electron microscopic observations of seven cases. Ophthalmology. 1985; 92: 512-522.
9. Spaide RF. Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in agerelated macular degeneration. Am J Ophthalmol. 2009; 147: 644-652.
10. Kim JT, Lee DH, Joe SG, et al. Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2013; 54: 3378-3384.
11. Regatieri CV, Branchini L, Carmody J, et al. Choroidal thickness in patients with diabetic retinopathy analyzed by spectraldomain optical coherence tomography. Retina. 2012; 32: 563-568.
12. Xu J, Xu L, Du KF, et al. Subfoveal choroidal thickness in diabetes and diabetic retinopathy. Ophthalmology. 2013; 120: 2023-2028.
13. Adhi M, Brewer E, Waheed NK, Duker JS. Analysis of morphological features and vascular layers of choroid in diabetic retinopathy using spectral-domain optical coherence tomography. JAMA Ophthalmol. 2013; 131: 1267-1274.
14. Arimura N, Otsuka H, Yamakiri K, et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology. 2009; 119: 921-926.
15. Sonoda Y, Arimura N, Shimura M, Sakamoto T. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion. Retina. 2011; 31: 290-297.
16. Terasaki H, Shirasawa M, Yamashita T, et al. Comparison of foveal microstructure imaging with different spectral domain optical coherence tomography machines. Ophthalmology. 2012; 119: 2319-2327.
17. Yamashita T, Yamashita T, Shirasawa M, et al. Repeatability and reproducibility of subfoveal choroidal thickness in normal eyes of Japanese using different SD-OCT devices. Invest Ophthalmol Vis Sci. 2012; 53: 1102-1107.
18. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol. 2008; 145: 854-861.
19. Zhou J, Cidlowski JA. The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids. 2005; 70: 407-417.
20. Schaaf MJ, Cidlowski JA. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol. 2002; 83: 37-48.
21. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001; 107: 135-142.
22. Annane D, Cavaillon JM. Corticosteroids in sepsis: from bench to bedside? Shock. 2003; 20: 197-207.
23. Liu Y, Mladinov D, Pietrusz JL, et al. Glucocorticoid response elements and 11 beta-hydroxysteroid dehydrogenases in the regulation of endothelial nitric oxide synthase expression. Cardiovasc Res. 2009; 81: 140-147.
24. Bhandari V, Choo-Wing R, Chapoval SP, et al. Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung. Proc Natl Acad Sci U S A. 2006; 103: 11021-11026.
25. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol. 2007; 143: 995-1002.
26. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol. 1999; 155: 421-428.
27. Terasaki H, Kase S, Shirasawa M, et al. TNF-a decreases VEGF secretion in highly polarized RPE cells but increases it in nonpolarized RPE cells related to crosstalk between JNK and NF-kB pathways. PLoS One. 2013; 8: e69994.
28. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011; 152: 686-694.
29. Sheth S, Rush R, Natarajan S, Gillies M. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema. Clin Experiment Ophthalmol. 2011; 39: 673-681.
30. Kook PE, Maier M, Schuster T, et al. Nine-month results of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular oedema: a retrospective analysis. Acta Ophthalmol. 2011; 89: 769-773.
31. Forte R, Cennamo GL, Finelli M, et al. Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema. Eye (Lond). 2010; 24: 1325-1330.
32. Kreutzer TC, Al Saeidi R, Kook D, et al. Comparison of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular edema. Ophthalmologica. 2010; 224: 258-264.
33. Isaac DL, Abud MB, Frantz KA, et al. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized doubleblind study. Acta Ophthalmol. 2012; 90: 56-60.
34. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol. 2008; 92: 76-80.